Navigation Links
Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
Date:4/19/2011

SAN DIEGO, April 19, 2011 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced today that AM152, the company's lead LPA1 antagonist, has been granted an orphan drug designation by the U.S. Food and Drug Administration for the treatment of idiopathic pulmonary fibrosis. Commonly referred to as IPF, this fibrotic disease affects the lungs of patients and their ability to breathe.

"This is an important development for Amira, and potentially patients suffering from IPF, as we continue to move this promising therapeutic candidate forward in development," said Bob Baltera, Chief Executive Officer.  "We are currently completing our Phase 1 studies with AM152 and expect to begin a Phase 2 study by the end of 2011 or in early 2012.  Currently there are no FDA-approved therapies for IPF, and we look forward to better understanding the potential therapeutic benefit of an LPA1 antagonist in this disease area."

AM152 is a lysophosphatidic acid (LPA) receptor 1 antagonist.  Activation of the LPA1 receptor by LPA has been implicated in a number of disease processes, including tissue fibrosis.  LPA1 receptor antagonists have displayed efficacy in a wide range of preclinical fibrosis models, including lung, skin, eye, liver and kidney.

About Orphan Drug Designation

The United States Orphan Drug Act of 1983 was created to promote and support the development of new drug therapies for diseases that affect fewer than 200,000 people in the United States.  Orphan Drug Designation provides a sponsor seven years of market exclusivity for the designated therapeutic indication in the United States, from the point at which the therapy is granted marketing approval.  Orphan Drug Designation also provides access to regulatory support from the FDA, potential FDA fee reductions and tax credits related to development expenses.

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases.  Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions.  Our team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and various fibrotic diseases.  Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease.  For more information, visit www.amirapharm.com.


'/>"/>
SOURCE Amira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor
2. Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist
3. Amira Pharmaceuticals Announces IND Submission for Novel LPA1 Antagonist, AM152, for Potential Use in Fibrotic Diseases
4. Amira Pharmaceuticals Named One of Most Promising Biotech Companies by FierceBiotechs Annual Fierce 15
5. Visage Imaging Releases Amira 5.3
6. Amira Announces AM103 and AM803 Patent Grant in the United Kingdom
7. Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom
8. Anti-Fibrotic Data from Amira Pharmaceuticals LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology
9. Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma
10. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amiras Lead DP2 Antagonist, AM211
11. Amira Pharmaceuticals Submits IND for Second DP2 Antagonist, AM461
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... -- AVACEN Medical , Inc. (AVACEN) announced that Frost ... Product Innovation Award for Its fibromyalgia pain management device. ... device market research by Frost & Sullivan,s industry experts. ... relief product, the AVACEN 100, offers a safe and effective ... ...
(Date:10/11/2017)... Texas , Oct. 11, 2017  Caris Life ... focused on fulfilling the promise of precision medicine, today ... has joined Caris, Precision Oncology Alliance™ (POA) as its ... cancer centers, the St. Jude Crosson Cancer Institute will ... advance the use of tumor profiling, making cancer treatment ...
(Date:10/10/2017)... EXTON, Pa. , Oct. 10, 2017   ... leader in innovative solutions for injectable drug administration, today ... of West,s ID Adapter for improving the intradermal administration ... the Fourth Skin Vaccination Summit in May 2017 by ... Team Lead, Polio Department, World Health Organization (WHO), and ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... On The Brink”: the Christian history of the United States and the loss of ... William Nowers. Captain Nowers and his wife, Millie, have six children, ten grandchildren, ... Navy. Following his career as a naval aviator and carrier pilot, he spent ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health & Wellness ... Moonlight to raise money for the American Heart Association Heart Walk. Teams of up ... work together to keep their treadmills moving for 5 hours. Treadmills will start at ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... in wound care advancements to physician colleagues, skilled nursing facility medical directors and ... the Treacherous Waters of Wound Care." , "At many of these conferences we ...
Breaking Medicine News(10 mins):